Hikma Pharmaceuticals Plc 11.2% potential upside indicated by Citigroup

Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential upside of 11.2% according to Citigroup.



Citigroup set a target price of 1,920 GBX for the company, which when compared to the Hikma Pharmaceuticals Plc share price of 1,705 GBX at opening today (03/02/2023) indicates a potential upside of 11.2%. Trading has ranged between 1,175 (52 week low) and 2,137 (52 week high) with an average of 429,366 shares exchanging hands daily. The market capitalisation at the time of writing is £3,775,312,800.

Hikma Pharmaceuticals PLC is a pharmaceutical company. The Company’s principal activities are the development, manufacturing, marketing and selling of a range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments: Injectables, Generics and Branded. Injectables segment supply hospitals across its markets with generic injectables, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). Generics segment supply oral and other non-injectable generic and specialty branded products in the United States retail market. Branded segment supply branded generics and in-licensed patented products in MENA. It also markets its products in Canada and, which includes approximately 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.